Starting Dose Guidance Should Allow Alternate Methods – Merck, Bristol
Executive Summary
FDA should expand on alternative methods for selecting a starting dose in clinical trials in addition to the algorithm recommended in a draft guidance, Merck and Bristol-Myers Squibb say in comments